Al Berg

Al Berg

Alexander (Al) Berg, PhD, PharmD, FCP
Vice President, Operations
Cognigen

About Alexander
Prior to joining Cognigen in 2019, Al was the Scientific leader for the Critical Path to TB Regimens (CPTR) Initiative, a consortium in partnership with the Bill and Melinda Gates Foundation which is aimed at improving global health by delivering new and novel regimens to treat the world-wide tuberculosis pandemic. Independent of CPTR, he also provided ad hoc consulting services to support new and generic drug programs. Al’s skills include scientific program management, early phase clinical development, clinical pharmacology, and pharmacometrics, with therapeutic area experience in tuberculosis, epilepsy, and oncology. Scientific interests include expanding the use of modeling and simulation to inform decision making in drug development programs for generic drugs and neglected diseases.

Latest Research by Alexander Berg